Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy. However, the company have advised that abemaciclib in this indication will no longer be progressing at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Decision Selected
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
08 May 2018 Suspended. Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy. However, the company have advised that abemaciclib in this indication will no longer be progressing at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties if the situation changes.
05 December 2017 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual